Laurie Millar

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme

Dragana Bugarski‐Kirola, Nakao Iwata, Snjezana Sameljak et al. · The Lancet Psychiatry · 2016 · 91 citations

Psychiatry, Psychotic Disorder, Psychotropic Medication +9

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

Paul Emery, William F. C. Rigby, Paul P. Tak et al. · PLoS ONE · 2014 · 81 citations · Full text

2126. Safety, Tolerability, and Pharmacokinetics (PK) in Healthy Participants Following Single Dose Administration of Zosurabalpin, a Novel Pathogen-Specific Antibiotic for the Treatment of Serious <i>Acinetobacter</i> Infections

Andreas Guenther, Laurie Millar, Amanda Messer et al. · Open Forum Infectious Diseases · 2023 · 15 citations · Full text

Mg Zosurabalpin, Pharmacotherapy, Antimicrobial Chemotherapy +23

A double-blind placebo-controlled trial of oxytocin receptor antagonist (Antocin) maintenance therapy in patients with preterm labor

Luis Sanchez‐Ramos, G. Valenzuela, Roberto Romero et al. · American Journal of Obstetrics and Gynecology · 1997 · 11 citations

Oxytocin Receptor Antagonist, Postpartum Hemorrhage, Fertility +13